Loading...
XNAS
EMBC
Market cap341mUSD
Oct 08, Last price  
5.75USD
1D
-2.71%
1Q
77.47%
IPO
-81.15%
Name

Embecta Corp

Chart & performance

D1W1MN
XNAS:EMBC chart
P/E
3.58
P/S
0.32
EPS
1.61
Div yield, %
10.43%
Shrs. gr., 5y
0.66%
Rev. gr., 5y
-0.09%
Revenues
1.08b
-3.80%
1,109,000,0001,085,500,0001,165,000,0001,129,500,0001,120,800,0001,123,100,0001,080,400,000
Net income
95m
+21.84%
432,000,000427,600,000414,800,000223,600,00070,400,00078,300,00095,400,000
CFO
192m
+436.97%
505,000,000498,500,000456,000,000412,200,00067,700,00035,700,000191,700,000
Dividend
Aug 27, 20260.01 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Key people

Chairman of the Board, President, Chief Executive Officer · since 2025
Jean Casner
Chief Human Resources Officer, Senior Vice President · since 2023
Ginny Blocki
Senior Vice President - Strategy · since 2024
Tom Blount
Senior Vice President and President, North America · since 2022
Shaun Curtis
Senior Vice President - Global Manufacturing, Supply Chain and Quality · since 2024
Jacob Elguicze
Chief Financial Officer, Senior Vice President · since 2022
Anthony Roth
Vice President, Chief Accounting Officer, Corporate Controller · since 2024
Slobodan Radumilo
Senior Vice President and President - International · since 2022
Jeffrey Mann
Senior Vice President, General Counsel, Product Development · since 2024
Lead Independent Director · since 2025
Independent Director · since 2022
Independent Director · since 2022
Milton Morris
Independent Director · since 2022
Independent Director · since 2022
Independent Director · since 2022
IPO date
Mar 21, 2022
Employees
1,900
Domiciled in
US
Incorporated in
US
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑092024‑092023‑092022‑092021‑092020‑092019‑09
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT